Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
Background: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
SAGE Publishing
2020-05-01
|
| Ráidu: | Therapeutic Advances in Medical Oncology |
| Liŋkkat: | https://doi.org/10.1177/1758835920915303 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|